UNSPSC 51351524: Medroxyprogesterone caproate

This classification denotes a therapeutic progestin with the molecular formula C28H42O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier GNC5BCM98A, chemically known as pregn-4-ene-3,20-dione, 6-methyl-17-((1-oxohexyl)oxy)-, (6.alpha.)-, but more generally known as medroxyprogesterone caproate, which bears US NIH Compound Identifier 62997. European Medicines Agency schedules medroxyprogesterone caproate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08699MIG.

Most nations, for tariff purposes, schedule medroxyprogesterone caproate under HS 29372300. SMILES: CCCCCC(=O)O[C@@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2C[C@@H](C4=CC(=O)CC[C@]34C)C)C)C(=O)C.

UNSPSC 51351524 Medroxyprogesterone caproate, a Commodity code, describes a specific injectable progestin pharmaceutical used for contraception and hormone replacement therapy that state and local governments procure through their health departments, Medicaid agencies, public health clinics, and correctional health systems to support family planning services, reproductive health programs, and inmate medical care. The product is a long-acting reversible contraceptive administered by injection, typically marketed under brand names such as Depo-Provera, and serves both routine clinical demand and episodic procurement spikes tied to public health initiatives or grant-funded family planning expansions.

The source contains no recent state and local contract opportunities tagged to this code, so current issuing-body patterns, geographic concentration, and representative recent solicitations cannot be characterized from available procurement records. The absence of recent postings does not indicate zero procurement activity — medroxyprogesterone caproate is a standard formulary item in state Medicaid programs and public health systems — but rather suggests that routine pharmaceutical purchasing by health agencies often flows through standing cooperative purchasing agreements, GPOs, or blanket contracts negotiated at the state or regional level rather than through posted competitive solicitations. Firms seeking entry into this market should monitor state health department RFQs and Medicaid pharmaceutical sourcing vehicles, and track cooperative purchasing catalogs managed by entities such as NCPA or regional health purchasing consortia.